Orphazyme: Summary of 2018, important year ahead
Arimoclomol in the NPC indication will drive the story in the near-term but Orphazyme has a broad pipeline with multiple potential value drivers in the longer term. In this update we go through the recent news items and look ahead at the next steps for the company.